Source: Hematology, Transfusion and Cell Therapy. Unidades: FMRP, FM, ICB
Subjects: FARMACOLOGIA, LEUCEMIA MIELOIDE AGUDA, APOPTOSE, MEDICAMENTO
ABNT
LIMA, Keli Cristina de et al. Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax. Hematology, Transfusion and Cell Therapy. São José do Rio Preto: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.htct.2021.01.004. Acesso em: 20 ago. 2024. , 2022APA
Lima, K. C. de, Vicari, H. P., Carlos, J. A. E. G., Silva, J. C. L. da, Pontes, L. L. de F., Rego, E. M., & Machado Neto, J. A. (2022). Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax. Hematology, Transfusion and Cell Therapy. São José do Rio Preto: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1016/j.htct.2021.01.004NLM
Lima KC de, Vicari HP, Carlos JAEG, Silva JCL da, Pontes LL de F, Rego EM, Machado Neto JA. Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax [Internet]. Hematology, Transfusion and Cell Therapy. 2022 ; 44( 1): 124-127.[citado 2024 ago. 20 ] Available from: https://doi.org/10.1016/j.htct.2021.01.004Vancouver
Lima KC de, Vicari HP, Carlos JAEG, Silva JCL da, Pontes LL de F, Rego EM, Machado Neto JA. Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax [Internet]. Hematology, Transfusion and Cell Therapy. 2022 ; 44( 1): 124-127.[citado 2024 ago. 20 ] Available from: https://doi.org/10.1016/j.htct.2021.01.004